Atea Pharmaceuticals Completes Patient Enrollment In Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir For COVID-19 In High-Risk Patients
Atea Pharmaceuticals 完成全球 3 期 SUNRISE-3 试验的患者入组,该试验评估了本尼氟布韦在高危患者中的应用 COVID-19
Atea Pharmaceuticals Completes Patient Enrollment In Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir For COVID-19 In High-Risk Patients
Atea Pharmaceuticals 完成全球 3 期 SUNRISE-3 试验的患者入组,该试验评估了本尼氟布韦在高危患者中的应用 COVID-19
使用浏览器的分享功能,分享给你的好友吧